Quince Therapeutics raises USD 115 million in private placement of Series C preferred shares

Reuters2026/08/17 10:27

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Quince Therapeutics priced a private placement, issuing 144,200 shares of Series C Non-Voting Convertible Preferred Stock for about $115 million.
Each Series C share converts into 52 common shares, subject to conditions tied to stockholder approval.
Financing included warrants for 72,100 Series C shares at an exercise price of $996.9 per share.
Warrant exercise could raise about $72 million in additional proceeds.
The financing closed May 21, 2026, alongside the Orphai acquisition announced May 18, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-353141), on August 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Quince Therapeutics raises USD 115 million in private placement of Series C preferred shares

You may also like

Crypto prices